BDR 165
Alternative Names: BDR-165Latest Information Update: 30 Jun 2022
At a glance
- Originator Ildong Pharmaceutical; MDimune
- Developer MDimune
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 22 Jun 2022 MDimune has patent protection for BioDrone® in USA, Europe, Japan, Korea and China before June 2022 (MDimune pipeline, June 2022)
- 22 Jun 2022 Preclinical trials in Cancer in South Korea (unspecified route) before June 2022 (MDimune pipeline, June 2022)
- 31 Jan 2020 MDimune signs a joint development agreement with Ildong Pharmaceutical for BDR 165 based on BioDrone® technology (MDimune pipeline, June 2022)